K2M Group Holdings, Inc. (NASDAQ:KTWO) (the “Company” or “K2M”), a
global leader of complex spine and minimally invasive solutions
focused on achieving three-dimensional Total Body Balance™, today
announced it will showcase its 3D spinal balance portfolio and
Balance ACS® Platform at the 25th International Meeting on Advanced
Spine Techniques (IMAST) in Los Angeles, CA, at Booth #29.
Additionally, the Company will host four interactive workshops
facilitated by distinguished leaders in spine surgery.
"K2M is excited to attend this year's IMAST, a prestigious
meeting for surgeons to explore the latest topics, technologies,
and techniques in spinal deformity," said John P. Kostuik, MD,
Chief Medical Officer and Co-founder at K2M. "Over the past year,
we have grown our product offering—as evidenced by our 100th
product milestone and our launch of BACS Patient-Specific Rods
& Rails at IMAST. We remain committed each day to inventing new
solutions that help surgeons improve the lives of people living
with spinal disease.”
At the meeting, K2M will showcase its comprehensive 3D spinal
balance portfolio. Products include the YUKON™ OCT Spinal System,
NILE® Alternative Fixation Spinal System, RAVINE® Lateral Access
System, EVEREST® MI and MI XT Spinal Systems, CHESAPEAKE®
Anterior-Lumbar Stabilization System, OZARK™ Cervical Plate
Systems, and more.
The Company will also feature Balance ACS (BACS®), which provides
solutions to help surgeons achieve balance of the spine by
addressing each anatomical vertebral segment with a 360-degree
approach to the axial, coronal, and sagittal planes, emphasizing
Total Body Balance as an important component of surgical
success.
K2M to Host Interactive Workshops in Diamond Salon
6
- Techniques for Correcting Cervical Spine
DeformitiesWednesday, July 11 (4:00–6:00 p.m.)Christopher
Ames, MD; Steven Glassman, MD; Jeffrey Gum, MD
- Using Spinopelvic Parameters to Optimize Correction in
the Adult PatientThursday, July 12 (12:30–1:30
p.m.)Christopher Ames, MD; Shay Bess, MD; Robert Lee, BSc,
FRCS
- Alternative Fixation Using Band
TechnologyThursday, July 12 (5:15–6:15 p.m.)Gregory
Mundis, MD; Burt Yaszay, MD
- Hybrid Approaches to Deformity SurgeryFriday,
July 13 (12:00–1:00 p.m.)Robert Lee, BSc, FRCS
For more information on K2M's complete product portfolio,
visit www.K2M.com. For more information on Balance ACS, visit
www.BACS.com.
About K2M Group Holdings, Inc.
K2M Group Holdings, Inc. is a global leader of complex spine and
minimally invasive solutions focused on achieving three-dimensional
Total Body Balance. Since its inception, K2M has designed,
developed, and commercialized innovative complex spine and
minimally invasive spine technologies and techniques used by spine
surgeons to treat some of the most complicated spinal pathologies.
K2M has leveraged these core competencies into Balance ACS, a
platform of products, services, and research to help surgeons
achieve three-dimensional spinal balance across the axial, coronal,
and sagittal planes, with the goal of supporting the full continuum
of care to facilitate quality patient outcomes. The Balance ACS
platform, in combination with the Company's technologies,
techniques and leadership in the 3D-printing of spinal devices,
enable K2M to compete favorably in the global spinal surgery
market. For more information, visit www.K2M.com and connect with us
on Facebook, Twitter, Instagram, LinkedIn and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements that
reflect current views with respect to, among other things,
operations and financial performance. Forward-looking
statements include all statements that are not historical facts
such as our statements about our expected financial results and
guidance and our expectations for future business prospects.
In some cases, you can identify these forward-looking statements by
the use of words such as, “outlook,” “guidance,” “believes,”
“expects,” “potential,” “continues,” “may,” “will,” “should,”
“could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,”
“anticipates” or the negative version of these words or other
comparable words.
Such forward-looking statements are subject to various risks and
uncertainties including, among other things: our ability to achieve
or sustain profitability in the future; our ability to demonstrate
to spine surgeons and hospital customers the merits of our products
and to retain their use of our products; pricing pressures and our
ability to compete effectively generally; collaboration and
consolidation in hospital purchasing; inadequate coverage and
reimbursement for our products from third-party payers; lack of
long-term clinical data supporting the safety and efficacy of our
products; dependence on a limited number of third-party suppliers;
our ability to maintain and expand our network of direct sales
employees, independent sales agencies and international
distributors and their level of sales or distribution activity with
respect to our products; proliferation of physician-owned
distributorships in the industry; decline in the sale of certain
key products; loss of key personnel; our ability to enhance our
product offerings through research and development; our ability to
maintain adequate working relationships with healthcare
professionals; our ability to manage expected growth; our ability
to successfully acquire or invest in new or complementary
businesses, products or technologies; our ability to educate
surgeons on the safe and appropriate use of our products; costs
associated with high levels of inventory; impairment of our
goodwill and intangible assets; disruptions to our corporate
headquarters and operations facilities or critical information
technology systems or those of our suppliers, distributors or
surgeon users; our ability to ship a sufficient number of our
products to meet demand; our ability to strengthen our brand;
fluctuations in insurance cost and availability; our ability to
remediate the material weaknesses in our IT general controls; our
ability to comply with extensive governmental regulation within the
United States and foreign jurisdictions; our ability to maintain or
obtain regulatory approvals and clearances within the United States
and foreign jurisdictions; voluntary corrective actions by us or
our distribution or other business partners or agency enforcement
actions; recalls or serious safety issues with our products;
enforcement actions by regulatory agencies for improper marketing
or promotion; misuse or off-label use of our products; delays or
failures in clinical trials and results of clinical trials; legal
restrictions on our procurement, use, processing, manufacturing or
distribution of allograft bone tissue; negative publicity
concerning methods of tissue recovery and screening of donor
tissue; costs and liabilities relating to environmental laws and
regulations; our failure or the failure of our agents to comply
with fraud and abuse laws; U.S. legislative or Food and Drug
Administration regulatory reforms; adverse effects associated with
the exit of the United Kingdom from the European Union; adverse
effects of medical device tax provisions; potential tax changes in
jurisdictions in which we conduct business; our ability to generate
significant sales; potential fluctuations in sales volumes and our
results of operations over the course of a fiscal year; uncertainty
in future capital needs and availability of capital to meet our
needs; our level of indebtedness and the availability of borrowings
under our credit facility; restrictive covenants and the impact of
other provisions in the indenture governing our convertible senior
notes and our credit facility; worldwide economic instability; our
ability to protect our intellectual property rights; patent
litigation and product liability lawsuits; damages relating to
trade secrets or non-competition or non-solicitation agreements;
risks associated with operating internationally; fluctuations in
foreign currency exchange rates; our ability to comply with the
Foreign Corrupt Practices Act and similar laws; increased costs and
additional regulations and requirements as a result of being a
public company; our ability to implement and maintain effective
internal control over financial reporting; potential volatility in
our stock price; our lack of current plans to pay cash dividends;
potential dilution by the future issuances of additional common
stock in connection with our incentive plans, acquisitions or
otherwise; anti-takeover provisions in our organizational documents
and our ability to issue preferred stock without shareholder
approval; potential limits on our ability to use our net operating
loss carryforwards; and other risks and uncertainties, including
those described under the section entitled “Risk Factors” in our
most recent Annual Report on Form 10-K filed with the SEC, as such
factors may be updated from time to time in our periodic filings
with the SEC, which are accessible on the SEC’s website at
www.sec.gov. Accordingly, there are or will be important
factors that could cause actual outcomes or results to differ
materially from those indicated in these statements. These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in this release and our filings with the SEC.
We operate in a very competitive and challenging environment.
New risks and uncertainties emerge from time to time, and it is not
possible for us to predict all risks and uncertainties that could
have an impact on the forward-looking statements contained in this
release. We cannot assure you that the results, events and
circumstances reflected in the forward-looking statements will be
achieved or occur, and actual results, events or circumstances
could differ materially from those described in the forward-looking
statements.
The forward-looking statements made in this press release relate
only to events as of the date on which the statements are made. We
undertake no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as required by law. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements and you should not
place undue reliance on our forward-looking statements. Unless
specifically stated otherwise, our forward-looking statements do
not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures, investments or other
strategic transactions we may make.
Media Contact:
Zeno Group on
behalf of K2M Group Holdings,
Inc. Christian
Emering,
212-299-8985
Christian.Emering@ZenoGroup.com
Investor Contact:
Westwicke
Partners on behalf of K2M Group Holdings,
Inc. Mike
Piccinino, CFA,
443-213-0500
K2M@westwicke.com
Grafico Azioni K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Storico
Da Mag 2023 a Mag 2024